Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Ajjai S AlvaPam K MangatElizabeth Garrett-MayerSusan HalabiDamien HansraCarmen J CalfaMaged F KhalilEugene R AhnTimothy L CannonPamela CrilleyJulie G FisherDerrick S HaslemSagun ShresthaKaitlyn R AntonelliNicole L ButlerSasha L WarrenAndrew L RygielShamika RanasingheSuanna Steeby BruinoogeRichard L SchilskyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Pembrolizumab monotherapy has antitumor activity in heavily pretreated patients with mBC characterized by HTMB. Our findings support the recent US Food and Drug Administration approval of pembrolizumab for treatment of patients with unresectable or metastatic solid tumors with HTMB without alternative treatment options.
Keyphrases
- drug administration
- metastatic breast cancer
- advanced non small cell lung cancer
- combination therapy
- small cell lung cancer
- squamous cell carcinoma
- single cell
- cancer therapy
- epidermal growth factor receptor
- locally advanced
- clinical trial
- risk factors
- climate change
- drug delivery
- radiation therapy
- human health
- replacement therapy